Biocryst Pharmaceuticals (BCRX) earnings, Nov 4, 2026: EPS +133%, stock −3.9%
In brief
Biocryst Pharmaceuticals reported on Nov 4, 2026. Earnings per share changed +133% year over year, 52.4% above the estimate; revenue +13%. The stock opened with a −1.7% gap and closed the day −3.9% (Nov 4, 2026). The stock is now 32.0% below its 52-week high, +6.4% over 12 months. Next report: Feb 24, 2027.
EPS vs estimate+52.4%
EPS, YoY+133%
Revenue, YoY+13%
Gap · day−1.7% · −3.9%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 5, 2026 | +4.7% | +0.6% |
| Nov 4, 2026 | −1.7% | −3.9% |
Next-quarter estimates, ratings and the BCRX chart are in the terminal.
Open the terminalFAQ
When is Biocryst Pharmaceuticals's next earnings report?
Feb 24, 2027. The date comes from daily data and is corrected if the company moves it.
How did Biocryst Pharmaceuticals stock react to the report?
Opening gap −1.7%, day's result −3.9%.
Did Biocryst Pharmaceuticals's earnings grow?
Earnings per share rose 133% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.